Press Release

Printer Friendly Version View printer-friendly version
<< Back

Histogenics Corporation to Present at Upcoming Industry Conferences


WALTHAM, Mass., May 16, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Management will be presenting at several upcoming industry conferences. 

  • 12thWorld Advanced Therapies & Regenerative Medicine CongressLondon, England (May 17-19, 2017)

Adam Gridley, Histogenics’ CEO, will be participating in several panels discussing regulatory strategies and capital raising and for regenerative medicine companies.  With over 600 participants, 200 speakers and 7 tracks of content, the congress is a vibrant platform for knowledge sharing in the areas of stem cells, gene therapy, T-cell receptors and gene editing. 

A presentation “Hybrid US/Japanese Clinical and Regulatory Strategies” is scheduled for Wednesday, May 17th, where Mr. Gridley will share the Company’s experience working with the Japanese regulatory authorities for Histogenics’ lead cell therapy product NeoCart.  Additionally, Mr. Gridley will be hosting a plenary roundtable discussion regarding “Analytical Considerations for Cellular Therapy Manufacturing” on Wednesday, May 17th. Lastly, a presentation “Public Market Fundraising for Regenerative Medicine Companies” is scheduled for Thursday, May 18th.

  • Alliance for Regenerative Medicine Cell and Gene ExchangeWashington, DC (May 22-23, 2017)

Stephen Kennedy, Histogenics’ CTO, will be participating on a panel on Tuesday, May 23rd discussing promising cell and gene therapy programs.  The Cell & Gene Exchange is a partnering meeting focused on bringing together the regulatory, business and patient advocacy communities. 

In conjunction with this meeting, Mr. Kennedy will also participate in a meeting of the Standards Coordinating Body for Gene, Cell and Regenerative Medicines and Cell-based Drug Discovery (SCB).  The SCB is a multi-stakeholder consortium in the cell and gene therapy sector working to support the development, dissemination, education and implementation of relevant standards and related deliverables via public-private partnerships and ongoing work with national and international consensus standards organizations.  The SCB’s goal is to serve as a source of information, knowledge, experience and data collection related to process, material and reference standards to enable more efficient and successful development, manufacture and testing of advanced therapies and cell-based drug discovery.  Mr. Kennedy was asked to join this committee in the first quarter of 2017 by the Alliance for Regenerative Medicine.

  • Forum for Innovative Regenerative Medicine (FIRM) – Regenerative Medicine Crossroad® #4 Conference – Tokyo, Japan (June 1, 2017)

Adam Gridley, Histogenics’ CEO, will be presenting a corporate overview including Histogenics’ recent progress negotiating a regulatory pathway for NeoCart in Japan.  The event is sponsored by the Regenerative Medicine Industrialization Tactical Committee of FIRM, and is designed to facilitate partnering and licensing discussions between innovative companies and Japanese regenerative medical companies in Japan. 

About Histogenics Corporation

Histogenics is a leading regenerative medicine company developing and commercializing novel tissue therapies that may offer more rapid and durable recoveries for patients with pain and loss of function due to musculoskeletal conditions.  Histogenics’ regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering and bioadhesives to create tissue ex-vivo.  Histogenics’ first investigational product candidate, NeoCart is designed to treat cartilage defects in the knee and is currently in Phase 3 clinical development.  NeoCart is designed to exhibit characteristics of articular, hyaline cartilage prior to and upon implantation into the knee and therefore does not rely on the body to make new cartilage.  As a result, NeoCart is the only product in development or on the market with a one-year primary superiority endpoint as compared to the standard of care.  There are more than 500,000 or more knee cartilage procedures in the United States each year, with many healthy active adults avoiding treatment as they seek other alternatives.  Left untreated, even a small cartilage defect can expand in size and progress to debilitating osteoarthritis, ultimately necessitating a joint replacement procedure.  Osteoarthritis is more common in adults over the age of 50, but the condition and precursors of the condition can be observed much earlier, and cartilage damage is believed to be one of the leading contributors of this disease.  For more information, please visit


Investor Relations
Tel: +1 (781) 547-7909

Primary Logo

Histogenics Corporation